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Abstract
Listeria monocytogenes (LM) is a gram-positive bacterium that is a common contaminant of processed meats and dairy
products. In humans, ingestion of LM can result in intracellular infection of the spleen and liver, which can ultimately lead to
septicemia, meningitis, and spontaneous abortion. Interleukin (IL)-23 is a cytokine that regulates innate and adaptive
immune responses by inducing the production of IL-17A, IL-17F, and IL-22. We have recently demonstrated that the IL-23/IL-
17 axis is required for optimal recruitment of neutrophils to the liver, but not the spleen, during LM infection. Furthermore,
these cytokines are required for the clearance of LM during systemic infection. In other infectious models, IL-22 induces the
secretion of anti-microbial peptides and protects tissues from damage by preventing apoptosis. However, the role of IL-22
has not been thoroughly investigated during LM infection. In the present study, we show that LM induces the production of
IL-22 in vivo. Interestingly, IL-23 is required for the production of IL-22 during primary, but not secondary, LM infection. Our
findings suggest that IL-22 is not required for clearance of LM during primary or secondary infection, using both systemic
and mucosal models of infection. IL-22 is also not required for the protection of LM infected spleens and livers from organ
damage. Collectively, these data indicate that IL-22 produced during LM infection must play a role other than clearance of
LM or protection of tissues from pathogen- or immune-mediated damage.
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Introduction
Listeria monocytogenes (LM) is an intracellular, gram-positive
bacterium found in soil and water and is a common contaminant
of processed meats and dairy products. Ingestion of LM results in
translocation of the bacterium through the intestinal epithelial
layer. Ultimately, LM disseminates through the blood, infecting
the spleen and liver. LM infection can cause septicemia and
meningitis in immunocompromised individuals, as well as
spontaneous abortions in pregnant women [1]. In the mouse
model of mucosal intra-gastric (i.g.) infection, LM is not able to
efficiently adhere to the epithelial layer and is thus not able to
easily pass through the intestine [1]. This can be overcome by
infecting mice through the i.g. route with high doses of LM [2,3,4]
or using the systemic intravenous (i.v.) route of infection [4]. The
systemic model of infection is widely used to study immune
responses to LM.
Both innate and adaptive immune responses to LM are
important for clearance of the pathogen and for protection against
re-exposure. Many cell types, cytokines/chemokines, and effector
molecules contribute to these immune responses. Although it is
known that the IL-12/IFN-c pathway is important for activation
of macrophages and clearance of LM, the recently discovered IL-
23 cytokine pathway has not been extensively studied during LM
infection. IL-23, a member of the IL-12 family of cytokines, shares
a p40 subunit with IL-12, but is also comprised of a unique p19
subunit [5,6]. IL-23 is secreted by macrophages and dendritic cells
in response to invading pathogens, including LM [7,8]. Although
IL-23 is in the IL-12 family, IL-23 does not have the same
functions as IL-12. Instead, IL-23 expands and maintains IL-17
secreting T cells, which are known to produce IL-17A, IL-17F,
and IL-22 [9]. IL-23 has been described to play a protective role
against extracellular or vacuole-bound pathogens such as Klebsiella
pneumoniae [10,11], Citrobacter rodentium [12,13], and Salmonella
enterica [14,15], as well as against infections with Toxoplasma gondii
[16,17] and Candida albicans [18,19,20]. We have recently shown
that IL-23 is required for the production of IL-17A and IL-17F
during LM infection and that the IL-23/IL-17 axis is required for
survival and clearance of LM from the spleen and liver [21]. We,
and others, have also established that the IL-23/IL-17 axis is
required for the optimal recruitment of neutrophils to the liver, but
not the spleen, during a primary LM infection [21,22]. The
mechanism by which IL-23 offers protection against LM in the
spleen, however, remains unknown.
IL-23 can also directly induce the production of IL-22 from T
cells, natural killer (NK) cells, NK T cells, and lymphoid tissue
inducer (LTi) cells [13,23]. IL-22 has the ability to induce the
production of antimicrobial peptides [9,24,23,25], as seen in
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[26]. These antimicrobial peptides can reduce bacterial burdens
and protect the host from death. In addition to inducing the
production of antimicrobial peptides, IL-22 can also protect tissues
against damage. In the Klebsiella pneumoniae model, production of
IL-22 was able to protect lung tissue [26]. IL-22 can also protect
hepatocytes against acute liver inflammation induced by ConA
[27].
A previous publication presented data showing that IL-22
deficient and wild-type C57Bl/6 (B6) mice did not differ in LM
burdens in the spleen or liver at day 3 post i.v. infection [27].
However, that study did not investigate the clearance of LM in IL-
22 deficient mice during later time-points or during secondary
immune responses. Our data using IL-23 deficient mice has shown
that increased bacterial burdens are not evident in these mice at
early time-points post infection. IL-23 deficient mice only begin to
show increased bacterial burdens at day 5 post infection, when
compared to B6 mice [21]. These facts would suggest that IL-22
deficient mice might only show increased bacterial burdens at later
time-points post LM infection. Furthermore, the IL-23/IL-22 axis
has been predominantly shown to provide protection at mucosal
surfaces, suggesting that this axis may be important during oral
LM infection. The current study investigates the production of IL-
22, and the role that IL-22 plays during primary and secondary
LM infection, using both systemic and mucosal routes of infection.
Materials and Methods
Ethics statement
Animal studies were performed under the approval of the
Institutional Animal Care and Use Committee at the University of
North Texas Health Science Center. The Office of Laboratory
Animal Welfare Assurance Number for The University of North
Texas Health Science Center Animal Facility is A3711-01. All
efforts were made to minimize suffering to the animals.
Mice
B6 mice were purchased from Charles Rivers/National Cancer
Institute. IL-23p19 knock out (KO) and IL-22 KO mice
backcrossed at least 8 times on a B6 background (Taconic) have
been previously described [28,29], and were bred at the University
of North Texas Health Science Center. Age and gender matched
male or female mice between 5 to 12 weeks of age were used for
each experiment. Mice were housed with food and water ad
libitum in sterile microisolator cages with sterile bedding at the
University of North Texas Health Science Center American
Association for the Accreditation of Laboratory Animal Care
accredited animal facility.
Listeria monocytogenes infections and quantification of
bacterial burden
LM 10403s was grown on brain-heart infusion (BHI) agar plates
(BD Bacto) and virulent stocks were maintained by passage
through B6 mice. To determine bacterial burdens in mouse
intestines during mucosal infection, streptomycin resistant LM
(LM/strep
r) was used. For infection of mice, log-phase cultures of
LM or LM/strep
r were grown in BHI broth, washed twice, and
diluted in PBS to the desired concentration. For primary systemic
infections, unless otherwise stated, mice were i.v. injected with
,1610
4 LM via the lateral tail vein. For secondary systemic
infections, mice were i.v. infected with ,1610
3 LM, then allowed
six weeks to recover and clear the primary infection before being
i.v. re-infected with ,1610
6 LM. For primary mucosal infections,
unless otherwise stated, mice were i.g. infected with ,1610
7 LM/
strep
r via the esophageal cavity using a gavage needle. For
secondary mucosal infections, mice were i.g. infected with
,1610
7 LM/strep
r, then i.g. re-infected six weeks later with
,1610
8 LM/strep
r. To determine LM colony forming units
(CFUs), spleens and livers from infected mice were homogenized
in sterile double distilled H2O. Small intestines from i.g. infected
mice were extracted by cutting below the stomach and above the
cecum, flushed with PBS to remove debris, and homogenized in
sterile double distilled H2O. Serial dilutions (1:10) of the tissues
were prepared and 50 ml of each dilution was plated on BHI or
BHI/strep agar plates. After overnight incubation at 37uC,
colonies were counted, and LM CFUs recovered from each tissue
were calculated.
In vitro procedures
Mouse serum was obtained by removing the supernatant from
whole blood following centrifugation at 14,000 rpm for 30 min.
For experiments using splenocytes for culture or direct ex vivo
staining, spleens were homogenized with frosted microscope slides
and red blood cells were lysed in Tris-ammonium chloride.
Splenocytes were cultured in complete RPMI 1640 medium
supplemented with 10% fetal calf serum (Atlanta Biologicals), L-
glutamine, vitamins, penicillin/streptomycin, nonessential amino
acids, and sodium pyruvate (all supplements from Invitrogen-
Gibco). Splenocytes were cultured in the presence of heat-killed
LM (HKLM) with a multiplicity of infection of 50:1 or 10 ng/mL
IL-23. Liver leukocytes were prepared as previously described
[30]. Isolation of liver leukocytes was performed after resuspend-
ing cell pellets obtained from homogenized livers in 35% Percoll
medium and layering the cells upon 67.5% Percoll medium. The
gradient was centrifuged at 6006 g for 20 minutes, and low-
density cells were collected from the gradient interface. Cell
culture was performed at 37uC in humidified air containing 5%
CO2.
IL-22 ELISA
ELISAs were performed on serum and filtered, cell-free
splenocyte supernatants. Quantification of IL-22 was performed
using antibodies from PeproTech. Cytokine levels were deter-
mined by comparison with standard curves generated from
recombinant IL-22 (PeproTech) and were analyzed using a Biotek
EL808 spectrophotometer.
Annexin V staining and alanine aminotransferase assays
Splenocytes and liver leukocytes were incubated at 4uC for
15 min with saturating amounts of CD45.2 FITC (BD Pharmin-
gen) and Fc block (BD Pharmingen). Cells were then resuspended
in binding buffer (BD Pharmingen), and Annexin V PE (BD
Pharmingen) were added. Data was acquired and analyzed within
an hour of staining using a Beckman Coulter Cytomics FC500.
Serum alanine aminotransferase (ALT) levels were quantified by
colorimetric ALT enzyme assays (Biotron Diagnostics Inc.)
according to manufacturer’s directions.
Immunohistochemistry and microscopy
Immunohistochemistry was performed as previously described
[31]. Briefly, 5-mm sections of frozen spleens and livers from LM
infected B6 and IL-22 KO mice were made using a Leica CM
1850 cryostat. Antibody combinations used were purified anti-
Ly6G (1A8) (BD Pharmingen) and Difco Listeria O polyserum
(Fisher Scientific). Anti-Ly6G antibody was developed with anti-
rat Alexafluor 594 (Molecular Probes) and Difco Listeria O
polyserum was developed with anti-rabbit Alexafluor 488 (BD
IL-22 and Listeria monocytogenes Infection
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e17171Pharmingen). Prolong Gold antifade reagent (Invitrogen) and a
cover slip were added to the stained tissues. To view the stained
tissue, an Olympus Ax70 fluorescence microscope was used and
images were captured with an Olympus DP70 digital camera.
Statistical analysis
Analyses of variances (ANOVAs) were conducted on the data
where appropriate. Bonferroni t-tests and Tukey-Kramer analyses
were used for post-hoc analyses. LM CFU data was log
transformed prior to analysis, and is represented as such in the
figures. Log rank analysis was used to analyze survival curves. A p
value of 0.05 or less was considered significant in all cases.
Results
LM induces IL-22 production during systemic infection
IL-22 has previously been shown to play a protective role during
certain mucosal bacterial infections [26,13]. To determine the role
ofIL-22 duringsystemicinfection,we firstsought to determineifIL-
22 is produced during LM infection. Serum and spleens were
harvested from uninfected (UI) B6 mice or B6 and IL-23p19 KO
mice that were i.v. infected with LM for 3 days. The concentration
of IL-22 was measured in serum and splenocyte culture superna-
tants stimulated with or without HKLM or IL-23. LM infection
induced IL-22 production in B6 mice in both the serum and the
spleen as compared to UI B6 mice. In IL-23p19 KO mice, the
amount of IL-22 was reduced in the serum and splenocyte culture
supernatants with or without HKLM compared to LM infected B6
mice (Fig. 1A, B, and C). Therefore, LM infection induces the
production of IL-22, and the production of IL-22 is dependent on
IL-23 during a primary systemic i.v. infection. However, there were
no differences in IL-22 production from IL-23 stimulated
splenocytes from infected B6 and IL-23p19 KO mice (Fig. 1D).
This suggests that the cells capable of producing IL-22 are still
present in IL-23p19 KO mice, but are not able to secrete IL-22 in
the absence of IL-23. A similar pattern of IL-22 secretion was
observed atdays5 and 7 post infection (p.i.)inserumandsplenocyte
supernatants, as well as in the liver (data not shown).
IL-22 is not required for survival during systemic LM
infection
Since IL-22 is being produced during LM infection and is
regulated by IL-23, we next wanted to determine if IL-22 has a
protective role during a systemic LM infection. To this end, B6,
IL-23p19 KO, and IL-22 KO mice were i.v. infected with
,3.5610
4 LM for a survival study. As previously established [21],
IL-23p19 KO mice were more susceptible than B6 mice (Fig. 2).
However, there were no differences in survival between B6 and IL-
22 KO mice, and no differences in weight loss (data not shown)
during LM infection, suggesting that IL-22 is not required for
survival during a systemic i.v. LM infection. To determine if IL-22
was important during a high-dose infection, B6 and IL-22 KO
mice were i.v. infected with ,10
5 LM. By day 4 p.i., 8/9 B6 and
9/9 IL-22 KO mice had succumbed to the infection. Collectively,
these data indicate that although IL-23 is required for protection
against i.v. LM infection, IL-22 is dispensable.
LM induces IL-22 production during mucosal infection
During the natural route of human infection, LM is ingested
from contaminated meats and dairy products. LM is able to move
Figure 1. The production of IL-22 during primary systemic LM infection requires IL-23. Serum and spleens were harvested from
uninfected B6 mice (UI B6) and B6 and IL-23p19 KO mice i.v. infected with ,1610
4 LM for 3 days. The concentration of IL-22 was measured using
ELISA in serum (A) and overnight splenocyte supernatants from un-stimulated (B), HKLM stimulated (C), or IL-23 stimulated (D) cultures. One-way
ANOVAs detected significant effects of mouse strain (p#0.05). An * indicates a significant difference from infected B6 (p#0.05). These data are
representative of two independent experiments. All data are expressed as the mean + SEM (n=5/group).
doi:10.1371/journal.pone.0017171.g001
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circulating blood to the spleen and liver. To mimic the route of
infection in humans, we utilized an oral mucosal model of
infection in mice. To determine if IL-22 production requires the
presence of IL-23 during mucosal LM infection, serum and spleens
were harvested from B6 and IL-23p19 KO mice that were i.g.
infected with LM/strep
r for 3 days. The concentration of IL-22
was measured in the serum and splenocyte culture supernatants
stimulated with or without HKLM or IL-23. In IL-23p19 KO
mice, the amount of IL-22 was reduced in the serum and
splenocyte culture supernatants with or without HKLM compared
to LM infected B6 mice (Fig. 3A, B, and C). Therefore,
production of IL-22 is dependent on IL-23 during a primary
mucosal LM infection. However, there were no differences in IL-
22 production in splenocytes re-stimulated with IL-23 (Fig. 3D).
This again suggests that the cells capable of producing IL-22 are
still present in IL-23p19 KO mice, but are not able to secrete IL-
22 in the absence of IL-23.
IL-22 is not required for survival during mucosal LM
infection
To discern if IL-22 was required for survival during a mucosal
LM infection, mice were i.g. infected with ,1610
8 LM/strep
r and
observed for 12 days. Weights and clinical signs of illness (posture
and condition of fur) of these mice were also observed. There were
no differences in survival (Fig. 4), weight (data not shown), or
clinical signs of illness (data not shown) between B6 and IL-22 KO
mice, suggesting that IL-22 production is not required for survival
during a primary mucosal LM infection.
IL-22 is not required for clearance of LM during infection
Although no differences were observed in overall survival
between B6 and IL-22 KO mice, IL-22 could still be impacting the
kinetics of clearance of LM from the spleen or liver during
infection. To test this possibility, B6 and IL-22 KO mice were
Figure 2. IL-22 is not required for survival during a systemic LM
infection. B6, IL-22 KO, and IL-23p19 KO mice were i.v. infected with
,3.5610
4 LM for a survival study. These data are combined from four
independent experiments. A log rank analysis detected a significant
difference between the survival curves of IL-23p19 KO mice and both B6
and IL-22 KO mice, (p#0.05), (B6 n=24; IL-22 KO n=24; IL-23p19 KO
n=9).
doi:10.1371/journal.pone.0017171.g002
Figure 3. The production of IL-22 during primary mucosal LM infection requires IL-23. Serum and spleens were harvested from B6 and IL-
23p19 KO mice i.g. infected with ,1610
7 LM/strep
r for 3 days. The concentration of IL-22 was measured using ELISA in serum (A) and overnight
splenocyte supernatants from un-stimulated (B), HKLM stimulated (C), or IL-23 stimulated (D) cultures. A two-way ANOVA detected significant effects
of mouse strain (p#0.05). An * indicates a significant difference from B6 (p#0.05). These data are representative of two independent experiments. All
data are expressed as the mean + SEM (n=4/group).
doi:10.1371/journal.pone.0017171.g003
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spleen and liver. There were no differences in LM CFUs between
B6 and IL-22 KO mice at days 1, 3, 5, and 7 p.i. (Fig. 5A, B, C,
and D). We next wanted to confirm that IL-23, but not IL-22, is
required for bacterial clearance from the spleen and liver. To this
end, B6, IL-23p19 KO, and IL-22 KO mice were infected with
LM and CFUs were determined at day 5 p.i. As previously
published [21], IL-23p19 KO mice had higher CFUs than B6
mice. IL-23p19 KO mice also had higher CFUs than IL-22 KO
mice, and there was no statistically significant difference between
B6 and IL-22 KO mice (Fig. S1). These data suggest that IL-22 is
not required for clearance of LM from the spleen or liver during a
systemic LM infection.
To determine the impact of IL-22 on bacterial clearance during
a mucosal LM infection, B6 and IL-22 KO mice were i.g. infected
with LM/strep
r and spleens, livers, and intestines were harvested
at days 1 and 3 p.i. There were no LM CFU differences between
B6 and IL-22 KO mice at days 1 and 3 p.i. (data not shown), again
suggesting that IL-22 is not required for clearance of LM during
mucosal infection.
IL-22 is not required for protection of tissues during LM
infection
While our data suggest that IL-22 is not required for bacterial
clearance during systemic or mucosal LM infection, other models
have found that IL-22 protects cells from apoptosis, thereby
limiting tissue damage [26,27,32,33]. However, the ability of IL-
22 to prevent apoptosis and tissue damage during LM infection is
unknown. The peak of apoptosis during LM infection is day 2 p.i.
[34], therefore we chose this time-point to investigate the
requirement of IL-22 for protection of splenocytes and liver
leukocytes from apoptosis. As evident in Fig. 6A, B and C,L M
infection induced a significant increase in apoptosis in splenocytes.
However, there were no differences in the overall percentage of
cells undergoing apoptosis in the spleens (Fig. 6A and C)o fB 6
and IL-22 KO mice at day 2 post i.v. infection. In addition, there
were no differences in the percentage of non-hematopoietic
epithelial cells (CD45.2-) undergoing apoptosis in the spleens of B6
and IL-22 KO mice during LM infection (Fig. 6B). Likewise,
although LM infection induced an increase in apoptosis in the
liver, there were no differences between percentages of apoptotic
cells between B6 and IL-22 KO mice (Fig. 6D, E, and F).
Furthermore, there were no differences in apoptosis between B6
and IL-22 KO mice at days 1, 3, and 5 p.i. (data not shown).
In order to more thoroughly investigate the role that IL-22
might be playing in preventing tissue damage during LM
infection, liver damage was assessed by measuring alanine
Figure 4. IL-22 is not required for survival during mucosal LM
infection. B6 and IL-22 KO mice were i.g. infected with ,1610
8 LM/
strep
r for a survival study. These data are combined from two
independent experiments. A log rank analysis did not detect a
significant difference between the survival curves of B6 and IL-22 KO
mice, (p.0.05), (n=13/group).
doi:10.1371/journal.pone.0017171.g004
Figure 5. IL-22 is not required for clearance of bacteria from the spleen and liver during a primary systemic LM infection. B6 and IL-
22 KO mice were i.v. infected with ,1610
4 LM. Spleens and livers were harvested and bacterial burdens were determined at day 1 (A), day 3 (B), day 5
(C), and day 7 (D) p.i. Two-way ANOVAs did not detect significant effects of mouse strain (p.0.05). These data are combined from two independent
experiments. All data are expressed as the mean + SEM (n=10/group).
doi:10.1371/journal.pone.0017171.g005
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serum ALT levels between B6 and IL-22 KO mice during systemic
LM infection at day 2 p.i. (Fig. 7), which is the peak of liver
damage during LM infection [35]. This result suggests that IL-22
does not play a role in protecting tissues from damage during
systemic LM infection. Similar results were observed at 1, 3, and 5
days post LM infection (data not shown).
Further visualization of LM induced damage in B6 and IL-22
KO mice during systemic infection was accomplished by perform-
ingimmunohistochemistry on livers obtained from miceinfected for
3 days with LM. LM lesions and neutrophils were clearly identified
in both B6 and IL-22 KO livers. However, no differences in the
number and size of lesions were apparent (data not shown).
Collectively, the data from apoptosis assays, ALT assays, and
immunohistochemistry suggest that IL-22 is not required for tissue
protection during a primary systemic LM infection.
IL-22 production does not require IL-23 during a
secondary LM infection
IL-22 production is dependent on IL-23 during primary
systemic and mucosal LM infections (Fig. 1 and 3). We were
interested in determining if IL-22 production was dependent on
IL-23 during a secondary systemic i.v. LM infection. To this end,
B6 and IL-23p19 KO mice were infected with LM and allowed six
weeks to recover. These immunized B6 and IL-23p19 KO mice
were then re-infected with LM and spleens were harvested at day 2
p.i. The concentration of IL-22 was measured in the serum and
splenocyte culture supernatants stimulated with or without HKLM
or IL-23. Unlike what was observed during the primary LM
infection (Fig. 1), there were no differences between B6 and IL-
23p19 KO mice (Fig. 8A, B, C, and D). These data suggest that
a factor other than IL-23 is able to induce the production of IL-22
during a secondary systemic LM infection.
IL-22 is not required for clearance of LM or tissue
protection during secondary infection
IL-22 is not required for clearance of LM from the spleen or
liver during a primary LM infection (Fig. 5). However, these data
do not preclude IL-22 from having a role during a secondary LM
infection. To determine if IL-22 impacts the clearance of LM after
a secondary exposure to the pathogen, B6 and IL-22 KO mice
were re-infected six weeks after a primary LM infection. There
were no differences in LM CFUs between B6 and IL-22 KO mice
in the spleen or liver at day 2 post secondary infection (Fig. 9). To
determine the impact of IL-22 on bacterial clearance during a
secondary mucosal LM infection, B6 and IL-22 KO mice were re-
infected via the mucosal i.g. route of infection six weeks after a
primary mucosal LM/strep
r infection. There were no differences
in LM/strep
r CFUs between B6 and IL-22 KO mice in the spleen,
liver, or intestine (data not shown).
Figure 6. IL-22 does not impact apoptosis in spleens during primary systemic LM infection. B6 and IL-22 KO mice were i.v. infected with
,1610
4 LM for 2 days. Splenocytes and liver leukocytes from uninfected B6 (UI B6), and LM infected B6 and IL-22 KO were harvested and the
percentage of apoptotic cells was determined by flow cytometry based on expression of Annexin V. The percentage of apoptosis in all splenocytes
(A) and non-hematopoietic, CD45.2-, cells (B) is shown. Representative Annexin V staining of splenocytes is shown in (C). The percentage of apoptosis
in all liver leukocytes (D) and non-hematopoietic, CD45.2-, cells (E) is shown. Representative Annexin V staining of liver leukocytes is shown in (F).
One-way ANOVAs detected significant effects when comparing uninfected to infected samples (p#0.05). An * indicates a significant difference from
uninfected B6 (p#0.05). These data are representative of two independent experiments. All data are expressed as the mean + SEM (n=5/group).
doi:10.1371/journal.pone.0017171.g006
Figure 7. IL-22 is not required for tissue protection in livers
during primary systemic LM infection. B6 and IL-22 KO mice were
i.v. infected with ,1610
4 LM for 2 days. Serum from uninfected B6 (UI
B6), and LM infected B6 and IL-22 KO mice was harvested and analyzed
with an ALT detection kit. One-way ANOVAs detected significant effects
when comparing uninfected to infected samples (p#0.05). An *
indicates a significant difference from uninfected B6 (p#0.05). These
data are combined from two independent experiments. All data are
expressed as the mean + SEM (n=10/group).
doi:10.1371/journal.pone.0017171.g007
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differences in the percentage of apoptotic cells in spleens between
B6 and IL-22 KO mice (data not shown). Likewise, there were no
differences in serum ALT levels between B6 and IL-22 KO mice
during secondary LM infection (data not shown), suggesting that
IL-22 is not required for limiting liver damage. Collectively, these
data suggest that IL-22 is not required for optimal bacterial
clearance or tissue protection during secondary LM infection.
Discussion
To date, the primary role discovered for IL-23 is to maintain
lymphocytes that secrete IL-17A, IL-17F, and IL-22 or to directly
induce the production IL-22 [9,6]. IL-22, a downstream cytokine
of IL-23, has been previously reported to be able to induce the
secretion of antimicrobial peptides [9,6] as well as protect tissues
from damage by preventing apoptosis [26,27]. IL-22 is induced
during certain infectious models including Salmonella enterica [14],
Toxoplasma gondii [36], Citrobacter rodentium [13], Klebsiella pneumoniae
[26], and in an induced model of colitis [37]. We now provide
evidence that IL-22 is produced during LM infection. During both
a primary systemic and primary mucosal infection, the optimal
production of IL-22 during LM infection requires IL-23. When
IL-23 was added back into splenocyte cultures from IL-23p19 KO
mice, the production of IL-22 was restored, suggesting that the
cells that are capable of producing IL-22 are present in IL-23p19
KO mice. This is in contrast to IL-17 secreting lymphocytes
during LM infection, which require IL-23 for maintenance and
differentiation [21]. Our data suggest that IL-23 is required for the
optimal production of IL-22 from splenocytes, but not for the
maintenance or differentiation of these cells. At day 2 post-
secondary LM infection, IL-22 production is not regulated by IL-
23. This suggests IL-22 is not completely dependent on IL-23 for
production during secondary exposure to LM, and another factor
is able to induce the production of IL-22. Previously published
literature suggests that IL-6 or IL-12 may also be able to induce
IL-22 secretion [32,29,38,27,39], providing evidence that IL-22
production is not exclusively associated with the IL-23/IL-17 axis
[40].
Figure 8. IL-23 is not required for IL-22 production during a secondary systemic LM infection. B6 and IL-23p19 KO were i.v. infected with
,1610
3 LM, then re-infected six-weeks later with ,1610
6 LM. Serum and spleens were harvested 2 days p.i. The concentration of IL-22 was
measured using ELISA in serum (A) and overnight splenocyte supernatants from un-stimulated (B), HKLM stimulated (C), or IL-23 stimulated (D)
cultures. A two-way ANOVA did not detect significant effects of mouse strain (p.0.05). These data are representative of two independent
experiments. All data are expressed as the mean + SEM (n=4/group).
doi:10.1371/journal.pone.0017171.g008
Figure 9. IL-22 is not required for clearance of bacteria from
the spleen and liver during a secondary systemic LM infection.
B6 and IL-22 KO mice were i.v. infected with ,1610
3 LM, then re-
infected six-weeks later with ,1610
6 LM. Spleens and livers were
harvested 2 days p.i. and bacterial burdens were determined. A two-
way ANOVA did not detect a significant effect of mouse strain (p.0.05).
These data are combined from two independent experiments. All data
are expressed as the mean + SEM (n=9/group).
doi:10.1371/journal.pone.0017171.g009
IL-22 and Listeria monocytogenes Infection
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and IL-22 KO mice during primary or secondary systemic or
mucosal LM infection. The equivalent bacterial clearance in B6
and IL-22 KO mice during a secondary LM infection implies that
IL-22 is not involved in the generation of effector T cells against
LM as previously shown [27]. Furthermore, these findings suggest
that IL-22 is not required for the optimal generation or
maintenance of memory T cells specific for LM. Although IL-22
is known to be able to induce the production of antimicrobial
peptides, this potential increased production of antimicrobial
peptides may not be required for bacterial clearance during LM
infection. Antimicrobial peptides, such as RegIIIc and b-defensins,
are important for LM clearance during mucosal infection [41,42].
Therefore, an alternative explanation may be that IL-22 is not
regulating the production of these antimicrobial peptides.
Congruent with our findings that IL-22 does not seem to be
playing a role in innate bacterial clearance during LM infection,
Zenewicz et al saw no differences in LM burdens between B6 and
IL-22 KO mice at day 3 p.i. [27]. Importantly, our data now show
that IL-22 is dispensable for clearance of LM at days 5 and 7 p.i.,
as well as during secondary infection. These results were also
obtained using oral infection with LM. Similar results showing that
IL-22 does not play a role in pathogen clearance were seen in
other infectious models, including parasite infection with T. gondii
and Schistosoma mansoni, bacterial infection with Mycobacterium avium
and Mycobacterium tuberculosis [40], as well as fungal infection with
Candida albicans [19].
While no differences in bacterial clearance were observed
between B6 and IL-22 KO mice, IL-22 has also previously been
shown to protect tissues against damage during infection with
Klebsiella pneumoniae or ConA stimulation [26,27]. However, we
have found that IL-22 is not required for spleen or liver protection
during primary or secondary systemic LM infection. A similar
result was also seen in the livers of mice infected with S. mansoni
and T. gondii, and in the lungs of mice infected with M. tuberculosis
and M. avium [40]. As mentioned previously, the natural human
route of infection for LM is an oral mucosal infection. IL-22 might
be playing a role in protecting the intestinal tissue during a
mucosal LM infection. During an oral T. gondii infection, the
intestines of WT mice had more pathology than the intestines of
mice treated with anti-IL-22 despite the fact that parasite burdens
were the same [40]. Even though there were no differences in LM
clearance from the intestine between B6 and IL-22 KO mice
during a mucosal oral infection, differences in intestinal tissue
damage may still exist. However, the observation of no differences
in weight loss between B6 and IL-22 KO mice during mucosal LM
infection indicates that IL-22 may not be required to protect
intestinal tissue from LM induced damage. Another possibility is
that IL-22 is required for an optimal acute phase response during
LM infection. It has been previously shown that over-expression of
IL-22 can lead to systemic effects in mice that are primarily related
to an acute phase response [43]. This possibility during LM
infection warrants further investigation. It is also possible that IL-
22 plays a novel role during LM infection.
We have previously published that IL-23 is required for
clearance of bacteria from the spleen and liver during systemic
LM infection. Additionally, we have shown that the IL-23/IL-17
axis has the ability to optimally recruit neutrophils to the liver, but
not the spleen, during a primary systemic LM infection [21].
These IL-17 recruited neutrophils are likely to be playing a role in
the clearance of LM from the liver (unpublished data). In the
current study, production of IL-22 did not influence the clearance
of LM from the liver or spleen. Therefore, it is likely that the IL-
23/IL-17/neutrophil axis, but not the IL-23/IL-22/antimicrobial
peptide axis, is important for LM resistance in the liver [21]. In
conclusion, while IL-22 is produced during LM infection and this
production is regulated by IL-23, the function of IL-22 currently
remains unknown during LM infection.
Supporting Information
Figure S1 Unlike IL-23, IL-22 is not required for
clearance of bacteria from the spleen and liver during
a primary systemic LM infection. B6, IL-23p19 KO, and
IL-22 KO mice were i.v. infected with ,1610
4 LM. Spleens and
livers were harvested and bacterial burdens were determined at
day 5 p.i. A two-way ANOVA detected a significant effect of
mouse strain (p,0.05). An * indicates a significant difference from
B6 and IL-22 KO mice (p#0.05). Data are expressed as the mean
+ SEM (n=5/group).
(TIFF)
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